Lite Strategy, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Lite Strategy, Inc. (LITS) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2024-06-30, per its 10-K filed 2024-09-19.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2024-09-19
- Lite Strategy, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-06-30 was $0.00.
- Lite Strategy, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-03-31 was $0.00.
- Lite Strategy, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-12-31 was $0.00.
- Lite Strategy, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Lite Strategy, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Lite Strategy, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $4.35M, a 98.58% increase from fiscal 2022.
- Lite Strategy, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $2.19M, a 74.81% decline from fiscal 2021.
- Lite Strategy, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $8.69M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2024-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-19 | $0.00 derived: sum of 2 quarters · filed 2024-09-19 | $0.00 derived: sum of 3 quarters · filed 2024-09-19 | $0.00 10-K · filed 2024-09-19 |
| 2024-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-09 | $0.00 derived: sum of 2 quarters · filed 2024-05-09 | $0.00 10-Q · filed 2024-05-09 | $0.00 derived: sum of 4 quarters · filed 2024-09-19 |
| 2023-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-13 | $0.00 10-Q · filed 2024-02-13 | $0.00 derived: sum of 3 quarters · filed 2024-09-19 | $0.00 derived: sum of 4 quarters · filed 2024-09-19 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2024-09-19 | $0.00 derived: sum of 3 quarters · filed 2024-09-19 | $0.00 derived: sum of 4 quarters · filed 2024-09-19 |
| 2023-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-19 | $0.00 derived: sum of 2 quarters · filed 2024-09-19 | $0.00 derived: sum of 3 quarters · filed 2024-09-19 | $4.35M 10-K · filed 2024-09-19 |
| 2023-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-09 | $0.00 derived: sum of 2 quarters · filed 2024-05-09 | $4.35M 10-Q · filed 2024-05-09 | $4.15M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-13 | $4.35M 10-Q · filed 2024-02-13 | $4.15M derived: sum of 3 quarters · filed 2024-02-13 | $6.54M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-09-30 | $4.35M 10-Q · filed 2023-11-09 | $4.15M derived: sum of 2 quarters · filed 2023-11-09 | $6.54M derived: sum of 3 quarters · filed 2023-11-09 | $6.54M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$197.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-26 | $2.19M derived: sum of 2 quarters · filed 2023-09-26 | $2.19M derived: sum of 3 quarters · filed 2023-09-26 | $2.19M 10-K · filed 2023-09-26 |
| 2022-03-31 | $2.39M 10-Q · filed 2022-05-23 | $2.39M derived: sum of 2 quarters · filed 2022-05-23 | $2.39M 10-Q · filed 2023-05-11 | $2.39M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-12-31 | $0.00 10-Q/A · filed 2022-05-23 | $0.00 10-Q · filed 2023-02-09 | $0.00 derived: sum of 3 quarters · filed 2022-11-14 | $0.00 derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $0.00 derived: sum of 3 quarters · filed 2022-11-14 | $0.00 derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-08 | $0.00 derived: sum of 2 quarters · filed 2022-09-08 | $0.00 derived: sum of 3 quarters · filed 2022-09-08 | $8.69M 10-K · filed 2022-09-08 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-23 | $0.00 derived: sum of 2 quarters · filed 2022-05-23 | $8.69M 10-Q · filed 2022-05-23 | |
| 2020-12-31 | $0.00 10-Q/A · filed 2022-05-23 | $8.69M 10-Q/A · filed 2022-05-23 | ||
| 2020-09-30 | $8.69M 10-Q/A · filed 2022-05-23 | |||
| 2020-06-30 | $0.00 10-K · filed 2022-09-08 | |||
| 2019-06-30 | $0.00 10-K/A · filed 2022-05-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |